Unichem Laboratories Q4 FY26 Results Published in Newspapers
Unichem Laboratories published its Q4 FY26 results on May 23, 2026. Consolidated Q4 income was ₹575.12 crore with ₹18.79 crore net profit. Full-year consolidated income reached ₹2,201.85 crore with ₹57.80 crore net profit. Standalone Q4 income was ₹356.24 crore with ₹10.91 crore net profit.
This is a standard regulatory filing for financial results publication, which is expected by investors and does not introduce new material information that would significantly impact the company's stock price.
The announcement is a routine publication of financial results and regulatory filings, with no significant positive or negative developments highlighted.
Unichem Laboratories Limited has announced the publication of its unaudited financial results for the quarter and audited financial year ended March 31, 2026. These results were published in the Mumbai editions of Business Standard and Mumbai Lakshdeep on May 23, 2026, in compliance with Regulation 47 of the Listing Regulations.
The company also provided a detailed extract of its financial performance. For the consolidated results for the quarter ended March 31, 2026, total income from operations stood at ₹575.12 crore, with a net profit after tax of ₹18.79 crore. For the full year ended March 31, 2026, consolidated total income was ₹2,201.85 crore, and net profit after tax was ₹57.80 crore.
Standalone figures for the quarter ended March 31, 2026, showed total income from operations at ₹356.24 crore and a net profit after tax of ₹10.91 crore. For the full year ended March 31, 2026, standalone total income was ₹1,412.29 crore, with a net profit after tax of ₹52.97 crore.
The company also noted that from April 30, 2025, Unichem Laboratories Limited has ceased to be a subsidiary of another entity. Additionally, a provision made for a fine and interest related to a European Commission demand was adjusted, with the interest amount recognized in the year ended March 31, 2026, under exceptional items.
What to do with a filing like this
Unichem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Unichem Laboratories Limited. Read the original for the full detail.